Your insurance denied Ozempic. Here is how to appeal it.

Why Ozempic gets denied

Ozempic (semaglutide, 0.5 to 2 mg weekly injection) received FDA approval in December 2017 for glycemic control in adults with type 2 diabetes, as an adjunct to diet and exercise. The SUSTAIN trial series documented significant HbA1c reduction; SUSTAIN-6 (2016) demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease, which in 2020 led to an FDA label update adding the cardiovascular outcomes indication. Despite a decade-long track record, insurers deny Ozempic at rates patients find baffling. The reason is almost never that the drug is inappropriate, it is that the prior authorization, the records, or the prescriber's documentation did not map precisely to the plan's coverage criteria. The denials cluster into a handful of patterns:

• Step therapy, try metformin or another agent first. Most plans require documented failure of metformin (or documented intolerance) as a first-line type 2 diabetes medication before they cover a GLP-1. If your prescriber did not include this documentation, or your records sit in a different chart, the plan triggers an automatic step-therapy denial.
• Prior authorization required or lapsed. Ozempic universally requires prior authorization. A PA that was never filed, a PA that expired at plan renewal, or a PA submitted without supporting clinical documentation (HbA1c values, type 2 diabetes diagnosis code) is one of the most common and most fixable denial types.
• Type 2 diabetes not documented to the plan's standard. The plan may require HbA1c above a certain threshold, explicit diagnosis coding (E11.x), or documentation that lifestyle modifications were tried. If the prescriber's notes used clinical shorthand or the wrong ICD-10 code, automated review flags it as non-qualifying.
• Off-label for weight loss, indication mismatch with Wegovy. Ozempic (semaglutide 0.5 to 2 mg) is approved for type 2 diabetes; Wegovy (semaglutide 2.4 mg) is approved for weight management. If Ozempic was prescribed off-label for weight loss, or a weight-loss code was submitted, the plan can deny on that basis. The cleaner appeal is grounded in the type 2 diabetes indication; for weight management, Wegovy is the on-label product to consider separately.
• Non-preferred formulary tier or quantity limit. The plan may cover Ozempic but place it in a non-preferred tier with higher cost-sharing, or restrict the quantity below the therapeutic dose. A formulary exception request, supported by documentation that preferred alternatives are clinically inadequate, can address tier restrictions.
• Cardiovascular indication not recognized. For patients with type 2 diabetes and established cardiovascular disease, SUSTAIN-6 and the 2020 FDA label update support Ozempic for cardiovascular risk reduction. Some plans do not automatically apply this. If your plan denies on "not medically necessary" grounds and you have documented cardiovascular disease, that indication is a separate and often stronger appeal angle.

How to appeal it

The pattern that wins is precision: make the medical reviewer's job a simple checkbox match against the plan's own criteria. For Ozempic, get the indication right first, the type 2 diabetes indication is the clean ground, and an off-label weight-loss flag is best resolved by pointing the appeal at the approved use (or at Wegovy for weight management).

Sources include your plan's published GLP-1 coverage policy and the Ozempic prescribing information. We cite the specific policy that applies to your plan when we build your appeal.

Ozempic denial: common questions